As SMYD2 substrates p53 and Rb are often found to be inactivated in cancer, it was hypothesized that if the methylation of these substrates by SMYD2 played a role in SMYD2-mediated proliferation then heightened sensitivity to LLY-507 would occur in cell lines with wild-type p53 or Rb. Here, RB1 is linked to cancer.